Reported Saturday, Cogent Biosciences Highlights Bezuclastinib Rapid, Deep, Sustained Improvement In Objective Measures Of Mast Cell Burden In SUMMIT NonAdvSM Study
Benzinga Newsdesk 11 months ago
News
Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline --Bezuclastinib demonstrates that
- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline --
- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients --
- New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time --
- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --
- Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Application (NDA) on track for submission in December 2025 --